The Resmed share price collapse is a buying opportunity according to this broker

This stock could be a healthy opportunity.

| More on:
Man sleeping with a sleep apnoea mask on.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Resmed (ASX: RMD) share price has sunk around 30% since the start of August 2023 and it's down by more than 40% from September 2021.

The ASX healthcare share specialises in providing treatments for sleep apnea, which the company describes as a "disorder in which the muscles in the throat relax to the point of collapse, restricting airflow. This causes breathing to become shallow and even stop for seconds or minutes at a time."

Resmed provides masks, machines and software that help people breathe better during the night and sleep better.

What's going wrong for Resmed shares?

Part of the problem for the company may be an overall decline in market sentiment for ASX healthcare shares. For example, in the past six months the CSL Limited (ASX: CSL) share price is down 15% and the Sonic Healthcare Ltd (ASX: SHL) share price is down 17%.

However, in investors' eyes, there may be specific trouble ahead for businesses that treat sleep apnea because of a concern that new weight loss drugs, such as ones that reduce appetite, could lead to fewer people needing sleep apnea treatment.

According to the Royal Australian College of General Practitioners, obesity is the largest risk factor when it comes to developing obstructive sleep apnea (OSA). It is estimated that 58% of moderate-to-severe OSA is due to obesity.

If a sizeable portion of the population were taken out of Resmed's potential customer base, it would theoretically reduce the growth prospects for the business and that would be a negative for Resmed shares.

Is the ASX healthcare share an opportunity?

The broker JPMorgan certainly thinks it's an opportunity, with an increase to its rating on the company to overweight, which essentially means a buy.

A price target is where a broker thinks the share price will be in 12 months from the time of the recommendation. According to reporting by The Australian, the broker has a price target of $26.50 on Resmed shares, which implies a rise of 13% from the current level.

That suggests a bit of a recovery but would also simply mean that the Resmed share price could linger at a lower level than where it was in the first half of 2023.

At this Resmed share price, I think it's possible that the market may have become too pessimistic too early about what may happen with Resmed's future growth and the effectiveness (and take-up) of weight loss drugs. Time will tell whether the market is right to be as pessimistic as it is currently with the ASX healthcare share.

JPMorgan Chase is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, JPMorgan Chase, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL and Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A man slumps crankily over his morning coffee as it pours with rain outside.
Materials Shares

Core Lithium shares sink 8% on broker downgrade

The team at Citi thinks investors should be selling this lithium miner's shares.

Read more »

Man sitting in a plane seat works on his laptop.
Broker Notes

Are ASX short sellers right about the Flight Centre share price?

The ASX 200 travel share has been a frequent flyer on the top 10 most shorted stocks list since 2022.

Read more »

a woman holds a facebook like thumbs up sign high above her head. She has a very happy smile on her face.
Broker Notes

Why Bell Potter just upgraded this ASX 200 share to a buy rating

This share is exposed to structural growth tailwinds according to its analysts.

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A diverse group of happy office workers join hands in a team high five in celebration of a job well done.
Broker Notes

3 ASX shares under $5 ready to break the ASX mould

Analysts are tipping big returns from these shares over the next 12 months.

Read more »

A smiling woman with a satisfied look on her face lies on a rug in her home with her laptop open and a large cup on the floor nearby, gazing at the screen. researching new ETFs
Cheap Shares

'Indiscriminately sold': The ASX shares that are ridiculously cheap right now

The experts at ICE Investors reckon the discounting of these stocks is 'unjustified'.

Read more »

A cute little boy, short in height, wearing glasses, old-fashioned bow tie and cardigan stands against a wall near a tape measure with his hand at the top of his head as though to measure his height.
Broker Notes

Are ASX short sellers right about Pilbara Minerals shares?

Let's see what some of the big brokers think.

Read more »

A woman smiles at the outlook she sees through binoculars.
Investing Strategies

Profit up 24%: 2 classic ASX 200 stocks looking good for 2024

This pair has been a staple for many portfolios in the past, but experts reckon they're representing excellent value for…

Read more »